Cancer stem cell and treatment of breast cancer
DOI:
https://doi.org/10.22034/JATE.2016.13Keywords:
Cancer, Stem cell, BreastAbstract
Cancer stem cell (CSC) has been identified as tumor cell which have the ability to self-renew and to make the heterogeneous ancestries of cancer cells. Cancer has long been observed as a heterogeneous collected cells. Collected evidence has recommended that CSC is talented of self-renewal and differentiation into numerous varieties of cancer cells. Cancer stem cells have many fundamental apparatuses of resistance to chemotherapeutic drugs, new tumor-targeted drugs, and radiation therapy, permitting them to live standard cancer treatments and to initiate tumor metastasis. Numerous molecular complexes and pathways have been discussed in survival cancer stem cells which includes expression of ATP-binding cassette (ABC) drug transporters, the motivation of the Wnt/β- catenin, Hedgehog, Notch. Tumor cells have been recognized and isolated in several cancers which include blood, breast, and pancreas, skin and prostate. It is often associated with chemo-resistance and radio-resistance which cause the failure of current treatment. In this review, we briefly try to present the meaning of cancer stem cell and treatment position of breast cancer.
References
1. Reya T, Morrison SJ, Clarke MF, and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
2. Dean M, Fojo T, and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
3. Hu Y and Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. American Journal of Cancer Research 2012; 2: 340-356.
4. Jones RJ, Matsui WH, and Smith BD. Cancer Stem Cells: Are We Missing the Target? Journal of the National Cancer Institute 2004; 96: 583-585.
5. Chen K, Huang Y-h, and Chen J-l. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732-740.
6. Dean M. ABC Transporters, Drug Resistance, and Cancer Stem Cells. Journal of Mammary Gland Biology and Neoplasia 2009; 14: 3-9.
7. Calcagno AM, Salcido CD, Gillet J-P, Wu C-P, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, and Ambudkar SV. Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. JNCI Journal of the National Cancer Institute 2010; 102: 1637-1652.
8. Naujokat C and Steinhart R. Salinomycin as a Drug for Targeting Human Cancer Stem Cells. Journal of Biomedicine and Biotechnology 201217.
9. Karami A, Tebyanian H, Goodarzi V, and Shiri S. Planarians: an In Vivo Model for Regenerative Medicine. International journal of stem cells 2015; 8: 128.
10. Takebe N, Harris PJ, Warren RQ, and Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
11. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, and Wicha MS. Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling. PLoS Biology 2009; 7: e1000121.
12. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, and Pelicci PG. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457: 51-56.
13. Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
14. Hope KJ, Jin L, and Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
15. Tang C, Ang BT, and Pervaiz S. Cancer stem cell: target for anti-cancer therapy. The FASEB Journal 2007; 21: 3777-3785.
16. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, and Simeone DM. Identification of Pancreatic Cancer Stem Cells. Cancer Research 2007; 67: 1030-1037.
17. O/'Brien CA, Pollett A, Gallinger S, and Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
18. Cho K, Wang X, Nie S, Chen Z, and Shin DM. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clinical Cancer Research 2008; 14: 1310-1316.
19. LaBarge MA. The Difficulty of Targeting Cancer Stem Cell Niches. Clinical cancer research : an official journal of the American Association for Cancer Research 2010; 16: 3121-3129.
20. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, and Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2010; 13: 109-118.
21. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, and Chambers AF. Notch1 inhibition alters the CD44(hi)/CD24(lo) population and reduces the formation of brain metastases from breast cancer. Molecular cancer research : MCR 2011; 9: 834-844.
22. Li K, Li Y, Wu W, Gordon WR, Chang DW, Lu M, Scoggin S, Fu T, Vien L, Histen G, Zheng J, Martin-Hollister R, Duensing T, Singh S, Blacklow SC, Yao Z, Aster JC, and Zhou B-BS. Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3. Journal of Biological Chemistry 2008; 283: 8046-8054.
23. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, and Lander ES. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening. Cell; 138: 645-659.
24. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, and Song E. Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer. PLoS ONE 2010; 5: e15630.
2. Dean M, Fojo T, and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
3. Hu Y and Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. American Journal of Cancer Research 2012; 2: 340-356.
4. Jones RJ, Matsui WH, and Smith BD. Cancer Stem Cells: Are We Missing the Target? Journal of the National Cancer Institute 2004; 96: 583-585.
5. Chen K, Huang Y-h, and Chen J-l. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732-740.
6. Dean M. ABC Transporters, Drug Resistance, and Cancer Stem Cells. Journal of Mammary Gland Biology and Neoplasia 2009; 14: 3-9.
7. Calcagno AM, Salcido CD, Gillet J-P, Wu C-P, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, and Ambudkar SV. Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. JNCI Journal of the National Cancer Institute 2010; 102: 1637-1652.
8. Naujokat C and Steinhart R. Salinomycin as a Drug for Targeting Human Cancer Stem Cells. Journal of Biomedicine and Biotechnology 201217.
9. Karami A, Tebyanian H, Goodarzi V, and Shiri S. Planarians: an In Vivo Model for Regenerative Medicine. International journal of stem cells 2015; 8: 128.
10. Takebe N, Harris PJ, Warren RQ, and Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
11. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, and Wicha MS. Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling. PLoS Biology 2009; 7: e1000121.
12. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, and Pelicci PG. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457: 51-56.
13. Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
14. Hope KJ, Jin L, and Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
15. Tang C, Ang BT, and Pervaiz S. Cancer stem cell: target for anti-cancer therapy. The FASEB Journal 2007; 21: 3777-3785.
16. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, and Simeone DM. Identification of Pancreatic Cancer Stem Cells. Cancer Research 2007; 67: 1030-1037.
17. O/'Brien CA, Pollett A, Gallinger S, and Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
18. Cho K, Wang X, Nie S, Chen Z, and Shin DM. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clinical Cancer Research 2008; 14: 1310-1316.
19. LaBarge MA. The Difficulty of Targeting Cancer Stem Cell Niches. Clinical cancer research : an official journal of the American Association for Cancer Research 2010; 16: 3121-3129.
20. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, and Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2010; 13: 109-118.
21. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, and Chambers AF. Notch1 inhibition alters the CD44(hi)/CD24(lo) population and reduces the formation of brain metastases from breast cancer. Molecular cancer research : MCR 2011; 9: 834-844.
22. Li K, Li Y, Wu W, Gordon WR, Chang DW, Lu M, Scoggin S, Fu T, Vien L, Histen G, Zheng J, Martin-Hollister R, Duensing T, Singh S, Blacklow SC, Yao Z, Aster JC, and Zhou B-BS. Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3. Journal of Biological Chemistry 2008; 283: 8046-8054.
23. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, and Lander ES. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening. Cell; 138: 645-659.
24. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, and Song E. Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer. PLoS ONE 2010; 5: e15630.
Downloads
Published
2019-12-07
How to Cite
Tebyanian, H. ., Karami, A. ., & Amani , J. . (2019). Cancer stem cell and treatment of breast cancer. The Journal of Applied Tissue Engineering, 3(1), 1–5. https://doi.org/10.22034/JATE.2016.13
Issue
Section
Review Articels
